Zinplava (bezlotoxumab)
Clostridioides (Clostridium) difficile Monoclonal Antibody Intravenous Vial (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: Bezlotoxumab is used to prevent the return of a severe intestinal infection due to a bacteria called C. difficile. Bezlotoxumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking the effects of toxins made by C. difficile bacteria during an infection.
Bezlotoxumab is not an antibiotic and will not work to treat bacterial infections. Your doctor will prescribe a separate antibiotic to treat your C. difficile infection. Carefully follow your doctor's directions for all your medications.
Generic name: bezlotoxumab
Pronunciation: (BEZ-loe-TOX-ue-mab)
Drug class: Clostridioides (Clostridium) difficile Monoclonal Antibody
Therapeutic class: Biologicals
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zinplava
Indications
The following indications are listed for Zinplava:
- Adjunct Therapy To Prevent Clostridioides Difficile Infection (CDI) Recurrence
Also known as: Adjunct Therapy To Prevent Clostridium Difficile Infection (CDI) Recurrence.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Zinplava 1,000 Mg/40 Ml Vial | Maintenance | Infuse 10 mg/kg over 60 minute(s) by intravenous route once. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Igg Antibodies And Derivatives/Efgartigimod-Alfa
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)
Igg Antibodies And Derivatives/Nipocalimab-Aahu
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Igg Antibodies And Derivatives/Rozanolixizumab-Noli
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)
DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Chronic heart failure
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
Less Frequent
- Hypertension
- Worsening of chronic heart failure
More Frequent
- Fever
- Headache disorder
- Nausea
Less Frequent
- Dizziness
- Dyspnea
- Fatigue
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Adjunct therapy to prevent clostridioides difficile infection (CDi) recurrence | ||
| A04.7 | ICD10CM | Enterocolitis due to clostridium difficile |
| A04.71 | ICD10CM | Enterocolitis due to clostridium difficile, recurrent |
| A04.72 | ICD10CM | Enterocolitis due to clostridium difficile, not specified as recurrent |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.